Opko健康 OPK 深 滬
等待開盤 11-26 09:30:00 美东时间
1.35
+0.050
+3.85%
華盛通- 最 高1.36
- 今 開1.30
- 成交量 271.65万股
- 最 低 1.295
- 昨 收 1.30
- 總市值 10.72亿
- 52周最高 2.035
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 1.11
- 委 比 -49.53%
- 總股本 7.94亿
- 歷史最高 19.20
- 量 比 0.79
- 振 幅 5.00%
- 歷史最低 0.8516
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JP Morgan Initiates Coverage On OPKO Health with Neutral Rating
JP Morgan analyst Brian Cheng initiates coverage on OPKO Health (NASDAQ:OPK) with a Neutral rating.
11-20 19:47
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
OPKO Health announced its participation in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City. OPKO management will engage in one-on-one meetings with investors and a fireside discussion on December 3rd at 12:00 p.m. Eastern time. Investors can contact their Piper Sandler representative to schedule meetings. OPKO is a multinational biopharmaceutical and diagnostics company focusing on large, rapidly grow...
11-19 21:05
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
2025年第三季度，Entera Bio宣布其骨质疏松治疗药物EB613获得FDA同意，将BMD作为注册性III期研究的主要终点。EB613的II期数据显示，该药物可显著提升 trabecular 和 cortical 骨指标，且在年轻绝经后女性中展现出一致疗效。此外，EB613下一代产品预计于2025年底启动I期试验。公司还展示了GLP-2在短 bowel综合征和OXM在肥胖症中的积极前临床数据。财务方面，截至9月底，公司现金及现金等价物为1660万美元，净亏损320万美元。
11-14 21:05
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
<p>ModeX Therapeutics and Regeneron Pharmaceuticals have entered into a collaboration to develop multispecific antibodies targeting multiple disease pathways. ModeX will receive USD $7 million upfront, plus potential milestone and royalty payments exceeding USD $200 million per molecule, with a potential total value over $1 billion. The MSTAR platform will be used to create innovative antibody candidates for indications like immunology, oncology,...
10-29 12:00
OPKO Health Q3 Earnings Preview
OPKO Health (NASDAQ:OPK) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is -$0.04 and the consensus revenue estimate is $165.74...
10-29 05:35
An OPKO Health's Modex Therapeutics Company Doses First Patient In Its Phase 1/2a Trial Of MDX2004, A First-In-Class Trispecific Antibody-fusion Protein For Advanced Cancers
First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ModeX Therapeutics
10-28 20:08
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
A Phase 1/2a clinical trial has begun with MDX2004, a novel trispecific antibody-fusion protein targeting CD3, CD28, and 4-1BB to enhance T cell activation for advanced cancers. This drug aims to rejuvenate cellular immunity by expanding stem and memory T cell populations, offering potential for diverse cancers and immune impairments. Two abstracts on MDX2004 will be presented at the 2025 SITC Annual Meeting. ModeX Therapeutics, an OPKO Health co...
10-28 12:00
